Tufts CSDD Releases March/April 2022 Impact Report
Tufts CSDD has released the latest version of its bi-monthly Impact Report. In this March/April 2022 editionm the focus is oncost variation and mis-estimation in clinical trial budgets.
Facing limited resources and increasing operating and workforce-related costs across expanding drug development portfolios, sponsor companies are seeking ways to reign in clinical trial costs. At the same time, protocol designs continue to become more complex, resulting in higher levels of inefficiency, greater patient recruitment and retention challenges, and unplanned and unbudgeted disruptions.
Based on the results of a recent working group study, this Tufts CSDD Impact Report examines clinical trial budgets and offers insight into the factors driving commonly observed variation and cost.
The full report is available for purchase here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
